Literature DB >> 2367323

The effect of sodium tauro-24,25-dihydrofusidate on the nasal absorption of human growth hormone in three animal models.

P A Baldwin1, C K Klingbeil, C J Grimm, J P Longenecker.   

Abstract

The ability of a novel permeation enhancer, sodium tauro-24,25-dihydrofusidate (STDHF), to increase the systemic delivery of human growth hormone (hGH) after intranasal administration was investigated in rat, rabbit, and sheep. Formulations of hGH with STDHF exhibited greatly enhanced nasal absorption at concentrations of STDHF above its critical micelle concentration. The increase in bioavailability was 11-fold in rats and in rabbits and 21-fold in sheep for formulations containing 0.5% STDHF as compared to those without STDHF. Glycocholate or taurocholate at 0.5% was three to five times less effective than STDHF at enhancing hGH absorption in rats. Additionally, the pulsatile absorption kinetics observed after intranasal delivery more closely resemble the endogenous secretory pattern of hGH than those obtained following subcutaneous administration.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2367323     DOI： 10.1023/a:1015885204249

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


  15 in total

1.  Effects of sodium taurodihydrofusidate on nasal absorption of insulin in sheep.

Authors:  J P Longenecker; A C Moses; J S Flier; R D Silver; M C Carey; E J Dubovi
Journal:  J Pharm Sci       Date:  1987-05       Impact factor: 3.534

2.  A new experimental method for evaluating drugs in the nasal cavity.

Authors:  H Salem; E Clemente
Journal:  Arch Otolaryngol       Date:  1972-12

3.  Catch-up growth following transfer from three times weekly im to daily sc administration of hGH in GH deficient patients, monitored by knemometry.

Authors:  M Hermanussen; K Geiger-Benoit; W G Sippell
Journal:  Acta Endocrinol (Copenh)       Date:  1985-06

4.  Increased growth rate following transfer to daily sc administration from three weekly im injections of hGH in growth hormone deficient children.

Authors:  K W Kastrup; J S Christiansen; J K Andersen; H Orskov
Journal:  Acta Endocrinol (Copenh)       Date:  1983-10

5.  The effects of permeation enhancers on the surface morphology of the rat nasal mucosa: a scanning electron microscopy study.

Authors:  R D Ennis; L Borden; W A Lee
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

6.  Nasal absorption of nafarelin acetate, the decapeptide [D-Nal(2)6)]LHRH, in rhesus monkeys. I.

Authors:  S T Anik; G McRae; C Nerenberg; A Worden; J Foreman; J Y Hwang; S Kushinsky; R E Jones; B Vickery
Journal:  J Pharm Sci       Date:  1984-05       Impact factor: 3.534

7.  Daily subcutaneous administration of human growth hormone in growth hormone deficient children.

Authors:  K Albertsson-Wikland; O Westphal; U Westgren
Journal:  Acta Paediatr Scand       Date:  1986-01

8.  Analyses of 24-hour growth hormone profiles in children: relation to growth.

Authors:  K Albertsson-Wikland; S Rosberg
Journal:  J Clin Endocrinol Metab       Date:  1988-09       Impact factor: 5.958

9.  Micellar properties of sodium fusidate, a steroid antibiotic structurally resembling the bile salts.

Authors:  M C Carey; D M Small
Journal:  J Lipid Res       Date:  1971-09       Impact factor: 5.922

Review 10.  Human pituitary growth hormone (hGH) therapy in growth hormone deficiency.

Authors:  S D Frasier
Journal:  Endocr Rev       Date:  1983       Impact factor: 19.871
View more
  12 in total

Review 1.  Absorption enhancers for nasal drug delivery.

Authors:  Stanley S Davis; Lisbeth Illum
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Tolerability and absorption enhancement of intranasally administered octreotide by sodium taurodihydrofusidate in healthy subjects.

Authors:  T Kissel; J Drewe; S Bantle; A Rummelt; C Beglinger
Journal:  Pharm Res       Date:  1992-01       Impact factor: 4.200

3.  The physicochemical properties, plasma enzymatic hydrolysis, and nasal absorption of acyclovir and its 2'-ester prodrugs.

Authors:  Z Shao; G B Park; R Krishnamoorthy; A K Mitra
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

4.  A semisynthetic Quillaja saponin as a drug delivery agent for aminoglycoside antibiotics.

Authors:  J Recchia; M H Lurantos; J A Amsden; J Storey; C R Kensil
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

5.  Development of a human nasal epithelial cell culture model and its suitability for transport and metabolism studies under in vitro conditions.

Authors:  U Werner; T Kissel
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

6.  Nasal administration of an ACTH(4-9) peptide analogue with dimethyl-beta-cyclodextrin as an absorption enhancer: pharmacokinetics and dynamics.

Authors:  N G Schipper; J C Verhoef; L M De Lannoy; S G Romeijn; J H Brakkee; V M Wiegant; W H Gispen; F W Merkus
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

7.  Cyclodextrins as nasal absorption promoters of insulin: mechanistic evaluations.

Authors:  Z Shao; R Krishnamoorthy; A K Mitra
Journal:  Pharm Res       Date:  1992-09       Impact factor: 4.200

8.  Nasal membrane and intracellular protein and enzyme release by bile salts and bile salt-fatty acid mixed micelles: correlation with facilitated drug transport.

Authors:  Z Shao; A K Mitra
Journal:  Pharm Res       Date:  1992-09       Impact factor: 4.200

9.  Enhancement of nasal delivery of a renin inhibitor in the rat using emulsion formulations.

Authors:  T T Kararli; T E Needham; G Schoenhard; D A Baron; R E Schmidt; B Katz; B Belonio
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

10.  The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer.

Authors:  W A Lee; R D Ennis; J P Longenecker; P Bengtsson
Journal:  Pharm Res       Date:  1994-05       Impact factor: 4.200
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.